Global Headquarters: Marlborough, Massachusetts, USA
Global locations: Fort Lee, New Jersey, Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada, Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc.
Ownership: Indirectly, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
Core Therapeutic Areas: Central Nervous System (CNS) and Respiratory
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. The Company has charted new paths to target life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological, and respiratory conditions.
Since 2010, Sunovion has contributed clinical advances and new treatment options, and has led advocacy and educational initiatives with cross-sector coalitions focused on the advancement of research, innovation and improvements in healthcare.
Advances in research innovation, treatment access, and advocacy and community outreach have included:
- Pioneering a unique approach to discovery in the CNS space based on a systems neurobiology platform that facilitates rapid clinical development;
- Developing and supporting leading medical education programs held regionally in the U.K. Europe, as well as the U.S. and Canada;
- Hosting annual Hands On! days of service, involving hundreds of employees donating thousands of volunteer hours to the local communities in which Sunovion employees live and work.
View our latest pipeline.
Sunovion Executive Leaders